Vaccine Development

Large molecule vector technology purification solutions presented at conference

Published in Gene Therapy Weekly, May 19th, 2005

In a presentation at the World Vaccine Congress, Dr. Helene Pora, Pall Corporation (PLL), described how the use of disposable and scalable technologies to purify large molecule vectors, such as for gene therapy and cancer vaccines, can help manufacturers streamline the process and overcome many of the unique challenges associated with vaccine development.

Viral vaccine development is a long and costly process governed by stringent regulatory controls. As the demand for vaccines increases globally, biopharmaceutical companies need to safely and reliably speed up development and production cycles that typically last 8 to 12 years and cost between $300 and $800...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-05-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry